Dimitry Nuyten
About Dimitry Nuyten
Dimitry S.A. Nuyten: Current Role as Chief Medical Officer at Arcus Biosciences
Dimitry S.A. Nuyten serves as the Chief Medical Officer at Arcus Biosciences, a position he assumed in August 2022. In this role, he is responsible for overseeing the company's clinical development programs. His role encompasses strategizing and guiding the medical aspects of Arcus Biosciences' projects, ensuring that they align with regulatory standards and clinical objectives. His extensive background in immuno-oncology and oncology clinical development significantly contributes to his current responsibilities.
Dimitry S.A. Nuyten: Education and Medical Training
Dimitry S.A. Nuyten holds an MD from the University of Groningen and a PhD from the University of Amsterdam. He trained as a radiation oncologist at the Netherlands Cancer Institute in Amsterdam. To further his expertise, he spent a year as a visiting scientist at Stanford University from 2004 to 2005. His educational background and training have provided a solid foundation in medical sciences and oncology, driving his subsequent professional achievements in the field.
Dimitry S.A. Nuyten: Previous Roles and Experience
Before joining Arcus Biosciences, Dimitry S.A. Nuyten held the position of Chief Medical Officer at both Nektar Therapeutics and Aduro Biotech. Prior to these roles, he was Vice President and Immuno-Oncology Development Leader at Pfizer until 2019. At Pfizer, he was responsible for the full development program and registrational strategy for Bavencio®, as well as leading early development for immuno-oncology. Earlier in his career, he served as Group Medical Director at Bristol-Myers Squibb, focusing on early development oncology projects.
Dimitry S.A. Nuyten: Contributions to Immuno-Oncology
Dimitry S.A. Nuyten has made significant contributions to the field of immuno-oncology. While at Pfizer, he was pivotal in overseeing the development program and registrational strategy for Bavencio®, an important therapeutic in the immuno-oncology space. His leadership in early development for immuno-oncology at Pfizer showcases his expertise and impact in advancing cancer treatment. His past roles at Nektar Therapeutics, Aduro Biotech, and Bristol-Myers Squibb further underscore his dedication and influence in this specialized field of medicine.